Valuation: Celcuity Inc.

Market Cap 279.5Cr 249.15Cr 230.79Cr 209.85Cr 393.77Cr 26TCr 400.24Cr 2.77TCr 1.09TCr 14TCr 1.05TCr 1.03TCr 44TCr P/E 2026 *
-11.2x
P/E 2027 * -24.3x
Enterprise Value 279.5Cr 249.15Cr 230.79Cr 209.85Cr 393.77Cr 26TCr 400.24Cr 2.77TCr 1.09TCr 14TCr 1.05TCr 1.03TCr 44TCr EV / Sales 2026 *
123x
EV / Sales 2027 * 8.62x
Free-Float
89.77%
Yield 2026 *
-
Yield 2027 * -
1 day+0.95%
1 week-13.26%
Current month-28.17%
1 month-29.14%
3 months-35.37%
6 months-53.36%
Current year-42.73%
1 week 53.54
Extreme 53.54
63.44
1 month 53.54
Extreme 53.54
88.68
Current year 53.54
Extreme 53.54
151.02
1 year 53.54
Extreme 53.54
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 01/01/2012
Chief Executive Officer 64 01/01/2012
Director of Finance/CFO 59 01/07/2017
Director TitleAgeSince
Chairman 64 01/01/2012
Director/Board Member 64 01/01/2012
Director/Board Member 67 01/02/2014
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Exercice

Director

500 0.0011%
01/10/26 Free

Director

893 0.0019%
14/08/26 Free

Chief Financial Officer

26,000 0.0562%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-13.26%+9.93%+470.06% 276.86Cr
+1.52%-7.19%+51.66%+69.99% 6.5TCr
+1.52%+6.83%+10.77%+79.30% 5.12TCr
+0.30%-0.46%+2.53%+61.89% 5.12TCr
-0.38%+1.40%+29.98%+42.37% 4.39TCr
+0.30%+5.64%+16.99%+133.30% 4.2TCr
+2.35%-6.08%+236.69%+528.10% 3.81TCr
+2.16%+9.87%+18.92%+59.70% 3.32TCr
+1.66%-4.39%+36.26%+6.29% 2.52TCr
+1.60%+2.21%+21.34%+28.00% 2.25TCr
Average +1.20%-1.71%+43.51%+147.90% 3.75TCr
Weighted average by Cap. +1.15%-0.28%+45.71%+115.83%

Financials

2026 *2027 *
Net sales 2.28Cr 2.03Cr 1.88Cr 1.71Cr 3.21Cr 216.12Cr 3.26Cr 23Cr 8.88Cr 112.96Cr 8.55Cr 8.37Cr 361.1Cr 32Cr 29Cr 27Cr 24Cr 46Cr 3.08TCr 46Cr 321.23Cr 126.32Cr 1.61TCr 121.69Cr 119.14Cr 5.14TCr
Net income -27Cr -24Cr -22Cr -20Cr -38Cr -2.56TCr -39Cr -267.69Cr -105.26Cr -1.34TCr -101.41Cr -99Cr -4.28TCr -11Cr -9.75Cr -9.03Cr -8.21Cr -15Cr -1.04TCr -16Cr -108.28Cr -43Cr -541.74Cr -41Cr -40Cr -1.73TCr
Net Debt - -
Projected Income Statement - Annual - Celcuity Inc.
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
19/26/19 $57.12 +0.95% 26,69,086
16/26/16 $56.58 -6.17% 43,42,458
15/26/15 $60.30 +0.67% 21,23,480
14/26/14 $59.90 -5.21% 24,41,318
13/26/13 $63.19 -4.04% 14,97,794
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Celcuity Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
57.12USD
Average target price
156.91USD
Spread / Average Target
+174.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Celcuity Inc.
  1. Stock Market
  2. Stocks
  3. CELC Stock